Sidst opdateret 19.05.2020
Klik på linket nedenfor, tryk derefter Ctrl + C eller højreklik for at kopiere det.
Version 3 (06.04.2020)
Denne vejledning er tiltænkt initial diagnostik og behandling af formodet COVID-19. Virussygdommen er først beskrevet i januar 2020, og der er endnu sparsom evidens på en række områder. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau.
Sundhedsstyrelsens side om COVID-19
Sundhedsstyrelsens retningslinjer for håndtering af COVID-19
Sundhedsstyrelsens COVID-19: Risikovurdering, strategi og tiltag ved epidemi i Danmark
Sundhedsstyrelsens vejledning: Personer med øget risiko for alvorligt COVID-19 sygdomsforløb
Dansk Selskab for Infektionsmedicins dokument: Patienter med øget risiko for et alvorligt COVID-19 sygdomsforløb
Klik her for flere resultater
Mohamed Hassany, Wael Abdel-Razek, Noha Asem, Mohamed AbdAllah, Hala Zaid
We read with interest the Correspondence by Ashleigh Tuite and colleagues.1 We thank them for their interest in estimating the coronavirus disease 2019 (COVID-19) burden in Egypt. However, their model-based calculations used the number of patients known on March 6, and the numbers of patients and deaths are continuously changing. Attempting to reach a more up-to-date estimate of the expected number of patients in Egypt, we used other assumptions according to real-life data.
Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.
Chokshi DA, Katz MH.
In a little more than 1 month, US society and its hospitals were transformed by coronavirus disease 2019 (COVID-19). The once-boisterous streets of New York City became quiet, while the hospital wards reverberated with the swooshes and beeps usually heard in intensive care units (ICUs). COVID-19 echoed that duality. There are so many outside the hospital who were silently infected, while so many fought for their lives in the hospital, struggling just to breathe.
Cutler DM, Nikpay S, Huckman RS.
This Viewpoint discusses the shifting landscape of health care financing, regulation, and delivery as a result of the coronavirus pandemic, and discusses regulatory and other changes that need to be in place if telehealth and physician practice and hospital mergers become the “new normal” once the pandemic is controlled.
Weissman DN, de Perio MA, Radonovich LJ, Jr.
Health care personnel who care for critically ill patients with suspected or confirmed novel coronavirus disease 2019 (COVID-19) routinely participate in procedures, such as endotracheal intubation, that may create infectious aerosols. Among persons infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, approximately 8% will require endotracheal intubation and mechanical ventilation.
Richardson S, Hirsch JS, Narasimhan M, et al.
This case series describes clinical characteristics, health services use, and outcomes of patients with confirmed coronavirus disease 2019 (COVID-19) cared for at 12 hospitals of a single health system in the New York City (NYC) area.
Bauchner H, Easley TJ, .
The COVID-19 pandemic has accounted for tens of thousands of deaths and ultimately will affect millions more people who will survive. There will be time to mourn the victims and care for the survivors. But it is also time to recognize and thank some of the heroes who have emerged so far.
Desai AN, Aronoff DM.
This JAMA Patient Page describes who should wear face masks during the COVID-19 pandemic and provides suggestions for making masks at home and wearing them properly.
Chow EJ, Schwartz NG, Tobolowsky FA, et al.
This study assessed the spectrum of initial symptoms at the onset of polymerase chain reaction–confirmed coronavirus disease 2019 (COVID-19) among health care personnel in King County, Washington.
Schrag D, Hershman DL, Basch E.
This Viewpoint proposes a framework for modifying cancer care in the midst of the COVID-19 pandemic that balances considerations about the time-sensitivity of patient need for visits and treatment, risk of infectious exposure, and hospital and staff capacity and stress.
Grabowski DC, Joynt Maddox KE.
This Viewpoint discusses the second surge of COVID-19 patients on postacute care facilities and offers suggestions on how the medical community and policy makers should prepare by ensuring adequate infrastructure, staff training, and protective equipment.
Merchant RM, Lurie N.
This Viewpoint discusses the ways social media can be used as a critical tool in managing the COVID-19 outbreak, such as by directing users to trusted sources and counteracting misinformation, and how it can transform aspects of preparedness and response for the future.
Bachireddy C, Chen C, Dar M.
This Viewpoint reviews options legally available to state Medicaid programs to respond to the COVID-19 pandemic, including increasing coverage of the uninsured, expanding telehealth capabilities, removing financial barriers to testing and treatment, and easing limits on drug prescriptions.
Qiang Wang, Zhao Hu
The coronavirus disease 2019 (COVID-19) broke out throughout the world now. The total number of deaths has been Over 88900 up to now. The patients with confirmed COVID-19 progressed to acute respiratory distress syndrome (ARDS) rapidly in an incident rate as high as 41.8%(Wu et al., 2020), and many of them require mechanic ventilation. In a cohort of an intensive care unit (ICU) from Italy, 1287 cases need respiratory support, and among them, 88% of patients (1150 cases) had to be supported with mechanical ventilation(Grasselli et al., 2020).
Tanusree Sharma, Masooda Bashir
Nature Medicine, Published online: 26 May 2020; doi:10.1038/s41591-020-0928-yMobile apps provide a convenient source of tracking and data collection to fight against the spread of COVID-19. We report our analysis of 50 COVID-19-related apps, including their use and their access to personally identifiable information, to ensure that the right to privacy and civil liberties are protected.
Sukbin Jang, Ji-Young Rhee
Since the COVID-19 outbreak started in China, most deaths occur in the elderly or people with underlying diseases. The pathogenesis of COVID-19 is still not well understood why the viral infections lead to respiratory failure with a high mortality rate(Gao et al., 2020). An excessive immune response contributes to COVID-19 pathogenesis and lethality(Gao et al., 2020, Jin et al., 2020). Recently, complement suppression may represent a therapeutic approach to treat COVID-19(Gao et al., 2020).
Di Wu, Jianyun Lu, Lan Cao, Xiaowei Ma, Qun Liu, Yanhui Liu, Zhoubin Zhang
The pandemic of Corona Virus Disease 2019 (COVID-19) is becoming a worldwide disaster. According to the WHO, more than 4 248 389 cases were reported and 294 046 deaths were conformed globally as of 14 May, 2020(WHO, 2020). It has been reported that humans may be more likely to be infected with different types of viruses through respiratory transmission. Here we report the protective effect to pneumonia while fighting against COVID-19.
Rutger A. Middelburg, Frits R. Rosendaal
Since the start of the outbreak of SARS-CoV-2 in December 2019, in the Hubei province in China, the virus has quickly spread across the world (Ahn et al., 2020; Bar-On et al., 2020; Dyer, 2020). As the virus spread, so did the COVID-19 disease that it causes. To curb the surge in COVID-19 related mortality, different governments enforced different measures for the containment of the epidemic (Yan et al., 2020; Pike and Saini, 2020). Comparing numbers of cases between countries is difficult, due to vast differences in testing policies.
Ariel L. Rivas, José L. Febles, Stephen D. Smith, Almira L. Hoogesteijn, George P. Tegos, Folorunso O. Fasina, James B. Hittner
The challenges associated with the COVID-19 pandemic may require novel approaches. Given the numerous asymptomatic infections reported in this disease, actions that focus on symptomatic individuals are prone to fail.(Nishiura and Linton, in press) Some classic concepts –e.g., ‘recovered’ and ‘contact tracing’−may not apply: patients regarded as recovered may be test-positive and people without a travel history may be infected.(Lan et al., 2020; CDC, 2020) To avoid these ambiguities, here an unambiguous metric was explored: mortality.
S. Zayet et al.
The clinical presentation of European patients with mild-to-moderate Covid-19 infection is still unknown.
There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug.
Since the outbreak of coronavirus disease (COVID-19) in Wuhan in December 2019, by March 10, 2020, a total of 80,932 confirmed cases have been reported in China. Two consecutively negative RT-PCR test results in respiratory tract specimens is required for the evaluation of discharge from hospital, and oropharyngeal swabs were the most common sample. However, false negative results occurred in the late stage of hospitalization, and avoiding false negative result is critical essential.
Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients' clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).
The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed.
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.
The 2019 novel coronavirus (2019-nCoV) causing an outbreak of pneumonia in Wuhan, Hubei province of China was isolated in January 2020. This study aims to investigate its epidemiologic history, and analyze the clinical characteristics, treatment regimens, and prognosis of patients infected with 2019-nCoV during this outbreak.
Northern European Conference on Travel Medicine (NECTM) 2020
Mødet udskudt på grund af COVID-19
3.06.2020 - 5.06.2020
ASM Microbe 2020
Aflyst på grund af COVID-19
18.06.2020 - 22.06.2020
Ph.d. forsvar ved Kristina Langholz Kristensen
International AIDS Conference (AIDS) 2020
6.07.2020 - 10.07.2020
International Liver Congress (ILC) 2020
27.08.2020 - 29.08.2020
COVID-19 retningslinje (2020)
National handlingsplan for antibiotika til mennesker (2017)
Retningslinjer til sundhedsprofessionelle vedr. håndtering af infektion med zikavirus (2019)
Antiviral behandling af hiv smittede personer (2019)
Ratio, rate, or risk?
28.05.2020The Lancet Infectious Diseases
Reducing transmission of SARS-CoV-2
27.05.2020Science Express TOC RSS Feed
Device-Associated Menstrual Toxic Shock Syndrome [Reviews]
27.05.2020CMR Current Issue
Taenia solium Cysticercosis and Its Impact in Neurological Disease [Reviews]
27.05.2020CMR Current Issue
Evaluation of World Health Organization–Recommended Hand Hygiene Formulations
27.05.2020Emerging Infectious Diseases Journal
Hvad synes Professor Jens Lundgren om"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV."?
Hvad synes Professor Troels Lillebæk om"The global prevalence of latent tuberculosis: a systematic review and meta-analysis."?
Hvad synes Professor Lars Østergaard om"Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial."?
Hvad mener Professor Thomas Benfield om artiklen"Oral versus Intravenous Antibiotics for Bone and Joint Infection."?
Hvad mener Professor Niels Obel om artiklen"Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis."?
Indtast din email for at tilmelde dig vores nyhedsbrev og hold dig opdateret om nyt på hjemmesiden.
© 2020 Dansk Selskab for Infektionsmedicin
version: 2.6.1 ● design: C P Fischer
Side indlæst på 2,028 s